IDO Inhibitor NLG919

Known as: GDC-0919, NLG-919, NLG919 
An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2016
024620142016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Over the last decade, tryptophan catabolism has been firmly established as a powerful mechanism of innate and adaptive immune… (More)
Is this relevant?
2017
2017
Chemotherapy drug (paclitaxel, PTX) incorporated in a dual functional polymeric nanocarrier, PEG-Fmoc-NLG, has shown promise as… (More)
Is this relevant?
Review
2017
Review
2017
Iron-containing enzymes such as heme enzymes play crucial roles in biological systems. Three distinct heme-containing dioxygenase… (More)
Is this relevant?
2016
2016
Indoleamine 2,3-dioxygenase 1 (IDO1), promoting immune escape of tumors, is a therapeutic target for the cancer immunotherapy. A… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Immunochemotherapy combines a chemotherapeutic agent with an immune-modulating agent and represents an attractive approach to… (More)
Is this relevant?
2015
2015
Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD… (More)
Is this relevant?
2014
2014
Background The enzyme Indoleamine 2,3-dioxygenase (IDO1) catalyzes the cleavage of L-tryptophan, resulting in the production of… (More)
Is this relevant?
2014
2014
  • Nature Biotechnology
  • 2014
 
  • table 1
Is this relevant?
2014
2014
  • Nature Biotechnology
  • 2014
 
  • table 1
Is this relevant?
2014
2014
  • Nature Biotechnology
  • 2014
 
  • table 1
Is this relevant?